Seeking Alpha

Aegerion Pharmaceuticals (AEGR +8.8%) trades up in reaction to a positive FDA staff report on...

Aegerion Pharmaceuticals (AEGR +8.8%) trades up in reaction to a positive FDA staff report on its drug lomitapide. The drug treats a rare genetic disorder that causes very high cholesterol, and the report said that AEGR's plan to manage risk associated with it supports approval in adults with the most life-threatening forms. The drug is due to be reviewed on Wednesday by a committee of non-FDA medical experts, and the FDA will make a final decision by the end of December.
Comments (1)
  • FocalPoint Analytics
    , contributor
    Comments (5806) | Send Message
     
    That's one way to reduce cholesterol... reduce the functionality of the liver, the organ most responsible for making cholesterol.
    15 Oct 2012, 11:34 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|